Fludarabine and once-daily intravenous busulfan for allogeneic bone marrow transplantation for Chediak-Higashi syndrome.

Abstract

An HLA-identical sibling bone marrow transplant was done for a patient with Chediak-Higashi syndrome. The preparative regimen included intravenous fludarabine (40 mg/m2/dx4) and busulfan (130 mg/m2/dx4). Busulfan was given once daily. Pharmacokinetic studies showed the area under the concentration-time curve of the once-daily intravenous busulfan was similar to that seen with the total daily dose administered with an every-6-hourly regimen. Toxicity was minimal. Myeloid engraftment occurred on day +17 and donor chimerism was complete. Fludarabine and once-daily intravenous busulfan is well tolerated and is adequate for engraftment of sibling transplant in Chediak-Higashi syndrome.

• Authors: Nancy Gordon, Craig A Mullen, Hai Tran, Laura Worth, David Gomez Almaguer, Ka Wah Chan
• Journal: Journal of pediatric hematology/oncology (J Pediatr Hematol Oncol) Vol. 25 Issue 10 Pg. 824-6 (Oct 2003) ISSN: 1077-4114 [Print] United States
• PMID: 14528111 (Publication Type: Case Reports, Journal Article)

Chemical References

• Vidarabine
• Busulfan
• fludarabine

Topics

• Bone Marrow Transplantation (immunology)
• Busulfan (administration & dosage, pharmacokinetics, therapeutic use)
• Chediak-Higashi Syndrome (surgery)
• Child, Preschool
• Graft vs Host Disease (drug therapy, immunology)
• Humans
• Injections, Intravenous
• Male
• Siblings
• Time Factors
• Vidarabine (analogs & derivatives, therapeutic use)